Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-07-23

Clinical Trial Update: Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing GP40071 to NovoRapid in type 1 diabetes shows efficacy and safety data after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GP40071
  • NovoRapid (insulin aspart)

Snippet

Sponsor: Geropharm | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Phase 3 | Status: COMPLETED